# HCRN GU22-598: what clinicians are saying

> 173 statements from 12 sources (1 podcast, 10 posts, 1 registry record), 87 of them from 14 confirmed clinicians, each linked to its source. Commentary checked Nov 17, 2026.

## Report

- Trial: Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder
- NCT ID: NCT06809140
- Registry: https://clinicaltrials.gov/study/NCT06809140
- Sponsor: Matthew Galsky
- Phase: Phase 2
- Status: Recruiting
- Drugs tested: enfortumab vedotin plus pembrolizumab
- Indication: muscle-invasive urothelial cancer of the bladder
- Version: v1.0.0, edition 1
- Accepted: 2026-11-17 UTC
- Last checked: 2026-11-17 UTC
- Release hash: 8b04816ef3cb2e1ec8f83963ca119838b152e7a6c567485a2464b13a2f450f44

## Counts

- Commentary sources screened: 20
- Sources cited by verified statements: 12
- Verified statements: 173
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 87
- Findings: 13
- Named people in screened sources (unnamed speakers and accounts not counted): 22
- Speakers cited: 22
- Cited speakers with a verified identity: 20
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 14
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 14
- By role and specialty (the abstract's specialty counts):
  - 8 physician, specialty not confirmed
  - 3 physician, Medical oncology
  - 1 physician, Radiation oncology
  - 1 physician, Surgical oncology
  - 1 physician, Urology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited distinguish HCRN GU22-598 by its stringent biopsy assessment, qualifying broader concern that apparent clearance may conceal cancer. Much of the debate concerns EV209: one physician supports maintaining planned EV–pembrolizumab exposure to isolate the effect of omitting surgery, while another favors earlier stopping for exceptional responders because of neuropathy risk. No target-trial outcomes are reported in the sources reviewed for this edition.

## Question clinicians left open

What evidence linking clinical to pathological complete response do clinicians need before clinical complete response can guide cystectomy omission after enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer?

From finding F1 (14 statements from 5 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Clinical complete response: why some clinicians question its use alone to omit cystectomy
  - 14 statements from 5 speakers in 6 sources, 1 of them a podcast or video.
  - 2 of the 5 named speakers in this finding hold this view, each a confirmed clinician.
  - 4 of the report's 14 cited clinicians.
- F2. Complete response: why some speakers ask if it proves durable local control and cure
  - 16 statements from 7 speakers in 5 sources, 1 of them a podcast or video.
  - 3 of the 7 named speakers in this finding hold this view.
  - 5 of the report's 14 cited clinicians.
- F3. Bladder sparing: where speakers split on fixed versus response-adapted duration
  - 20 statements from 9 speakers in 2 sources, 1 of them a podcast or video.
  - 9 of the 9 named speakers in this finding take a side on this question: 1 on one side, 8 on the other.
  - 7 of the report's 14 cited clinicians.
- F4. Bladder sparing: what most clinicians highlight about toxicity with prolonged treatment
  - 27 statements from 7 speakers in 4 sources, 1 of them a podcast or video.
  - 6 of the 7 named speakers in this finding hold this view, each a confirmed clinician.
  - 7 of the report's 14 cited clinicians.
- F5. CtDNA/utDNA: most speakers question readiness, but some propose guided care
  - 16 statements from 7 speakers in 3 sources, 1 of them a podcast or video.
  - 4 of the 7 named speakers in this finding hold this view; 3 of the 7 hold its caveat, “some propose guided care”.
  - 6 of the report's 14 cited clinicians.
- F6. Surgery omission: most speakers value trials, but most note a trial's limits
  - 21 statements from 5 speakers in 3 sources, 1 of them a podcast or video.
  - 4 of the 5 named speakers in this finding hold this view; 4 of the 5 hold its caveat, “most note a trial's limits”.
  - 3 of the report's 14 cited clinicians.
- F9. Bladder preservation: what speakers say
  - 25 statements from 9 speakers in 4 sources, 1 of them a podcast or video.
  - 6 of the report's 14 cited clinicians.
- F10. VOLGA: where speakers split on using future duration data across regimens
  - 24 statements from 4 speakers in 3 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding take a side on this question: 3 on one side, 1 on the other.
  - 3 of the report's 14 cited clinicians.
- F13. Perioperative MIBC: why speakers favor more individualized treatment
  - 9 statements from 3 speakers in 4 sources, 1 of them a podcast or video.
  - 3 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 14 cited clinicians.

### Beyond the trial population

- F7. Radiation and salvage: where clinicians split on local treatment after clinical CR
  - 11 statements from 3 speakers in 2 sources, 1 of them a podcast or video.
  - 2 of the 3 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician.
  - 3 of the report's 14 cited clinicians.
- F8. After clinical CR: which options most speakers would test for bladder sparing
  - 6 statements from 3 speakers in 2 sources, 1 of them a podcast or video.
  - 2 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 14 cited clinicians.
- F11. T4 response: some clinicians question clinical CR; a speaker proposes stage limits
  - 11 statements from 4 speakers in 2 sources, 1 of them a podcast or video.
  - 2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 4 holds its caveat, “a speaker proposes stage limits”.
  - 3 of the report's 14 cited clinicians.
- F12. Bladder sparing: how speakers use earlier and metastatic studies as context
  - 11 statements from 4 speakers in 5 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding hold this view.
  - 3 of the report's 14 cited clinicians.

4 of the 13 findings and 28 of the 173 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 14 | 17 | 6 | 5 | 3 |
| F2 | 16 | 14 | 5 | 7 | 3 |
| F3 | 20 | 17 | 2 | 9 | 3 |
| F4 | 27 | 23 | 4 | 7 | 4 |
| F5 | 16 | 16 | 3 | 7 | 3 |
| F6 | 21 | 24 | 3 | 5 | 4 |
| F9 | 25 | 26 | 4 | 9 | 3 |
| F10 | 24 | 32 | 3 | 4 | 5 |
| F13 | 9 | 5 | 4 | 3 | 3 |
| F7 | 11 | 13 | 2 | 3 | 4 |
| F8 | 6 | 7 | 2 | 3 | 3 |
| F11 | 11 | 13 | 2 | 4 | 3 |
| F12 | 11 | 6 | 5 | 4 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 6 | 2 | 0 | 2 | 4 | 18 | 0 | 4 posts and articles, 1 podcast or video, 1 registry |
| F2 | 9 | 3 | 1 | 0 | 3 | 18 | 2 | 3 posts and articles, 1 podcast or video, 1 registry |
| F3 | 17 | 1 | 1 | 0 | 1 | 22 | 3 | 1 post or article, 1 podcast or video |
| F4 | 7 | 8 | 3 | 1 | 8 | 31 | 1 | 3 posts and articles, 1 podcast or video |
| F5 | 10 | 6 | 0 | 0 | 0 | 18 | 2 | 2 posts and articles, 1 podcast or video |
| F6 | 12 | 2 | 1 | 1 | 5 | 26 | 1 | 1 post or article, 1 podcast or video, 1 registry |
| F9 | 15 | 5 | 3 | 0 | 2 | 28 | 2 | 3 posts and articles, 1 podcast or video |
| F10 | 11 | 8 | 0 | 1 | 4 | 33 | 7 | 2 posts and articles, 1 podcast or video |
| F13 | 6 | 2 | 1 | 0 | 0 | 9 | 0 | 3 posts and articles, 1 podcast or video |
| F7 | 4 | 3 | 0 | 0 | 4 | 16 | 3 | 1 podcast or video, 1 registry |
| F8 | 4 | 2 | 0 | 0 | 0 | 7 | 0 | 1 post or article, 1 podcast or video |
| F11 | 5 | 3 | 0 | 0 | 3 | 14 | 1 | 1 post or article, 1 podcast or video |
| F12 | 5 | 0 | 0 | 1 | 5 | 11 | 4 | 4 posts and articles, 1 podcast or video |

### Trial dimensions

- Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC: F1 (10 shared claims), F5 (1 shared claims), F6 (3 shared claims), F9 (1 shared claims)
- Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response: F1 (1 shared claims), F2 (9 shared claims), F5 (1 shared claims), F6 (2 shared claims), F9 (5 shared claims)
- Secondary endpoints: F2 (7 shared claims), F4 (2 shared claims), F6 (1 shared claims), F9 (4 shared claims), F10 (1 shared claims)
- Population and setting: F1 (1 shared claims), F6 (1 shared claims), F10 (1 shared claims), F13 (5 shared claims)
- The comparison: F1 (3 shared claims), F2 (1 shared claims), F3 (3 shared claims), F6 (5 shared claims), F9 (1 shared claims)
- Safety and tolerability: F3 (2 shared claims), F4 (23 shared claims), F5 (1 shared claims), F9 (1 shared claims), F10 (1 shared claims)
- Design and conduct: F1 (2 shared claims), F2 (2 shared claims), F3 (3 shared claims), F6 (16 shared claims), F9 (5 shared claims), F10 (3 shared claims), F13 (1 shared claims)

## Abbreviations

- CR: complete response
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 15 sections | Paid |
| Verified statements with short source quotes and links | 173 | Paid |
| Who said each statement: the cited speakers | 22 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 14 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 20 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 12 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 14 of the 22 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC | discussed | 10 | 5 |
| Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response | discussed | 10 | 3 |
| Secondary endpoints | discussed | 9 | 4 |
| Population and setting | discussed | 14 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 15 | 2 |
| Safety and tolerability | discussed | 24 | 3 |
| Design and conduct | discussed | 27 | 2 |
| ctDNA, utDNA and multimodal selection for bladder preservation | discussed | 19 | 4 |
| Systemic-treatment duration and the contribution of postoperative therapy | discussed | 44 | 3 |
| Patient priorities, quality of life and the burden of retaining the bladder | discussed | 13 | 3 |
| Routine-care adoption, informed consent and prospective evidence | discussed | 16 | 5 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 111 statements · 64%** | | | |
| Podcasts | 111 | 1 | 1 |
| **Posts · 60 statements · 35%** | | | |
| X threads | 60 | 10 | 19 |
| **Primary sources · 2 statements · 1%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 2 | 1 | not screened |

- Screened window: 2025-06-27 to 2026-11-14
- Cited window: 2025-06-27 to 2026-11-14
- Retrieved: 2026-11-17

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder
- Registry: NCT06809140 (https://clinicaltrials.gov/study/NCT06809140)
- Study IDs: HCRN-GU22-598
- Sponsor: Matthew Galsky
- Collaborators: Seagen Inc., Astellas Pharma Inc, Merck Sharp & Dohme LLC, Icahn School of Medicine at Mount Sinai
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Recruiting
- Enrollment: 75 (estimated)
- Start: 2025-04-07 (actual)
- Primary completion: 2027-11 (estimated)
- Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC (9 weeks)
- Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response (2 years)
- Intervention: Enfortumab vedotin (drug)
- Intervention: Pembrolizumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about current treatment perspectives on selective bladder sparing in muscle-invasive bladder cancer; a view on response assessment and treatment duration when considering bladder sparing after systemic therapy for muscle-invasive bladder cancer; a question about the lack of comparative evidence for selective bladder sparing with systemic treatment; a remark on the provenance of relayed commentary about bladder-sparing treatment for muscle-invasive bladder cancer; a view on the practical ease of administering EV–pembrolizumab versus platinum chemotherapy; a view on the relative administration burden of enfortumab vedotin plus pembrolizumab versus platinum chemotherapy.
- 22 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- The sources reviewed for this edition contain registry methods and commentary, not an outcome report for NCT06809140. No target-trial efficacy, safety or equivalence conclusion can be drawn from these views.
- The most detailed debate concerns the separate EV209 study. Its 240-patient descriptions, treatment-assessment schedule and methodological defenses must not be treated as the target protocol.
- Some episode passages cannot be attributed to a named speaker. Guest lists and recurring transcript labels do not resolve who said those passages.
- The sources are not a representative sample of HCPs. Source totals, reposts, parallel-language accounts and repeated appearances by the same people do not establish prevalence, independence or consensus.
- Several figures were recalled approximately, questioned or used hypothetically. In particular, treatment-completion and mortality exchanges do not establish reliable exposure-specific death rates.
- Earlier-study results, metastatic observations, alternative regimens and proposed biomarker-defined strategies remain attributed context; they do not become results or validated selection rules for this trial.
- The discussion uses EV209 or EV-209, and one reply uses EV208. These descriptions concern a separate surgery-omission study and must not be merged with the target HCRN GU22-598 protocol.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-17 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-17 UTC. No changes.

## Offer

- Size: Standard · 173 verified statements · 87 from 14 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (20 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/hcrn-gu22-598-nct06809140
- Agents: POST https://www.erudio.com/api/orders with {"report": "hcrn-gu22-598-nct06809140", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=hcrn-gu22-598-nct06809140

## Cite

Erudio Health. HCRN GU22-598 (NCT06809140): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 17, 2026. https://www.erudio.com/reports/hcrn-gu22-598-nct06809140

## Questions

### How much does the HCRN GU22-598 report cost?

One edition costs $1,250 (Standard · 173 verified statements · 87 from 14 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the HCRN GU22-598 report cover?

173 statements from 12 sources (1 podcast, 10 posts, 1 registry record), 87 of them from 14 confirmed clinicians, each linked to its source. Commentary checked Nov 17, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the HCRN GU22-598 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "hcrn-gu22-598-nct06809140" }) previews it and create_order({ "report": "hcrn-gu22-598-nct06809140", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the HCRN GU22-598 report?

Edition 1 (version 1.0.0), accepted Nov 17, 2026 UTC; last checked for new commentary Nov 17, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.json
- Markdown: https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/hcrn-gu22-598-nct06809140/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "hcrn-gu22-598-nct06809140"}`
